Pegcetacoplan, a pegylated peptide that inhibits C3 (36), also showed good activity in a phase 2 trial in CAD and wAIHA with IgG + C DAT positivity, and a phase 3 study has been announced in CAD (NCT05096403). Here, SLC6A3 is linked to cold agglutinin disease.